GlassScriptPhysician profile
Rodrigo A Duralde
NPI 1265484208
$1,098.29
in general payments reported to CMS, 2019-2025
12 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $68.18 · 2021: $36.88 · 2022: $60.57 · 2023: $223 · 2024: $61.48 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $761.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $393.52 | 2019-2025 | Proclaim |
| Boston Scientific Corporation | $265.16 | 2022-2025 | Superion Indirect Decompression System, General - Pain Management, Varithena Administration Pack |
| Biotronik Nro, INC. | $108.10 | 2025 | Prospera |
| Medtronic, INC. | $85.81 | 2021-2025 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $73.28 | 2023-2024 | Belbuca, Xtampza |
| Foundation Fusion Solutions, LLC | $32.23 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $27.70 | 2025 | |
| Curonix LLC | $27.33 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Avanos Medical | $27.30 | 2019 | |
| Nevro Corp. | $23.63 | 2024 | Senza |
| Medtronic USA, INC. | $19.52 | 2020 | |
| International Rehabilitative Sciences, INC | $14.71 | 2025 | Rs-4i Plus With Intersperse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Duralde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.